BCL2 Inhibition in Leukemia
EP. 1: CLL: Patient Evaluation and Risk Stratification
June 25th 2019
EP. 2: Venetoclax's Role in Frontline CLL Management
June 25th 2019
EP. 3: Optimizing Frontline Therapy Selection and Follow-Up in CLL
June 25th 2019
EP. 4: Current Therapeutic Paradigm for Relapsed-Refractory CLL
June 25th 2019
EP. 5: BCL2 Inhibition in CLL: Managing Toxicity and Administration
June 25th 2019
EP. 6: Is There Still a Role for Frontline Chemoimmunotherapy in CLL?
June 25th 2019
EP. 7: Chronic Lymphocytic Leukemia: Future Directions in Care
June 25th 2019
EP. 8: Initiating Therapy in Patients With CLL
June 25th 2019
EP. 9: Chronic Lymphocytic Leukemia: Frontline Therapy Selection
June 25th 2019
EP. 10: Selecting Therapy for Relapsed/Refractory CLL
June 25th 2019
EP. 11: Venetoclax's Role in Relapsed/Refractory CLL
June 25th 2019
EP. 12: Venetoclax's Role in Frontline Management of CLL
June 25th 2019
EP. 13: Managing BCL2 Inhibitor AEs in Chronic Lymphocytic Leukemia
June 25th 2019
EP. 14: CLL: Logistical Considerations for Venetoclax Administration
June 25th 2019
EP. 15: CLL: The Current and Future Paradigms of BCL2 Inhibition
June 25th 2019
EP. 16: Venetoclax + Azacitidine in Frontline AML Management
June 25th 2019
EP. 17: AML: Managing AEs With Venetoclax + Azacitidine
June 25th 2019
EP. 18: AML: Optimizing Selection and Use of Venetoclax + Azacitidine
June 25th 2019
EP. 19: Novel Strategies in Acute Myeloid Leukemia Management
June 25th 2019
